Environmental sustainability: the EIPG perspective
Piero Iamartino Although the impact of medicines on the environment has been highlighted since the 70s of the…
EMA’s pilot scheme for academic and non-profit development of ATMPs
by Giuliana Miglierini Advanced therapy medicinal products (ATMPs) are often developed by academic and non-profit organisations, because of…
Approvals and flops in drug development in 2023
by Giuliana Miglierini Approvals and flops in drug development in 2023 The European Medicines Agency published its annual…
The ICMRA collaborative hybrid inspection pilot (CHIP)
by Giuliana Miglierini Hybrid inspections emerged during the pandemic as a new way to approach the assessment of…
The first Union list of critical medicines
by Giuliana Miglierini The first version of the Union list of critical medicines was published on 12 December…
The drug shortage situation – EIPG’s point of view
by Maurizio Battistini The shortage of medicines has been a major concern in the countries of the European…